Home › Products › Oncology › Nelabin 250mg Injection
Nelabin 250mg Injection
Salt Composition: NELARABINE
- Manufacturer: MSN LABORATORIES (INDIA)
- Pack Size: 1 VIAL(s)
- Dosage Form: INJECTION
- Strength: 250MG
- Prescription Required
- Storage: Store at a controlled temperature (20-25°C) away from direct sunlight and moisture. If a dose is missed, consult a healthcare professional before making up for it. In case of overdose, seek immediate medical attention due to the risk of severe toxicity.
₹10079.00₹12271.88
Inclusive of all taxes
Product Introduction
Nelabin 250mg Injection contains Nelarabine, an antineoplastic medicine used in the treatment of certain types of blood cancers, including T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). It works by interfering with the growth and survival of cancer cells, leading to their destruction.
As a chemotherapy medicine, Nelabin 250mg Injection should only be administered under strict medical supervision due to its powerful effects and possible side effects. Before starting treatment, your doctor may evaluate your kidney and liver function, neurological health, and blood cell counts to ensure safe use.
This medicine is not recommended for individuals with severe neurological conditions or those who are allergic to Nelarabine or any of its ingredients. Pregnant and breastfeeding women should inform their doctor before treatment, as this medicine may cause serious harm to the fetus or infant. Follow all safety precautions and medical advice during therapy to achieve the best possible treatment outcomes
Uses
Nelabin 250mg Injection is FDA-approved for the treatment of: T-cell acute lymphoblastic leukemia (T-ALL) T-cell lymphoblastic lymphoma (T-LBL)
How it works
This medication belongs to the class of antimetabolites and acts by interfering with DNA synthesis within rapidly dividing cancer cells. Once inside the body, it is converted into its active form, which integrates into the DNA of malignant cells, disrupting their ability to multiply. This ultimately leads to cell death and reduces the progression of the disease. Due to its targeted mechanism, it is highly effective in treating specific blood malignancies while requiring careful monitoring to manage its associated risks.
How to Use
Nelabin 250mg Injection is available as an intravenous (IV) infusion and is administered by a healthcare professional in a clinical setting. The dosage is carefully determined based on the patientâs body surface area, overall health status, and response to treatment. It is typically given in cycles, allowing for adequate intervals between doses to enable the body to recover and minimise potential side effects.
Side Effects
Common Side Effects: Fatigue Nausea and vomiting Decreased appetite Fever Muscle weakness Serious Side Effects: Severe bone marrow suppression Peripheral neuropathy (tingling, numbness, or weakness in limbs) Severe infections due to low white blood cell count Cognitive and coordination impairments Seizures (in rare cases)
Expert Tips
Patients undergoing treatment should maintain regular follow-ups to monitor blood counts and overall health. Neurological symptoms such as confusion or muscle weakness should be reported immediately. Adequate hydration is essential to minimise kidney-related side effects. As it suppresses immune function, avoiding crowded places and exposure to infections is advised. Supportive therapies and lifestyle modifications can enhance tolerance and improve treatment outcomes.
References
- 1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Nelarabine. [Updated 2020 May 1]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548515/ 2. Boddu PC, Senapati J, Ravandi-Kashani F, Jabbour EJ, Jain N, Ayres M, Chen Y, Keating MJ, Kantarjian HM, Gandhi V, Kadia TM. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies. https://pubmed.ncbi.nlm.nih.gov/36448227/ 3. Kathpalia M, Mishra P, Bajpai R, Bhurani D, Agarwal N. Efficacy and safety of nelarabine in patients with relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis. https://pubmed.ncbi.nlm.nih.gov/35727338/ 4. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021877s005lbl.pdf
Safety Advice
Pregnancy: unsafe Nelabin 250mg Injection may cause fetal harm; effective contraception is required during treatment.
Lungs: Consult your doctor Patients with pre-existing lung conditions should be monitored for respiratory complications before taking Nelabin 250mg Injection.
Breastfeeding: unsafe Nelabin 250mg Injection is not recommended due to the risk of serious infant complications.
Disclaimer
The information provided on this page is intended for general informational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Self-medication can be harmful. Med For Rare does not endorse self-diagnosis or self-treatment.